Login to Your Account



Other News To Note


Friday, December 2, 2011
• BioMarin Pharmaceutical Inc., of Novato, Calif., said it completed the buyback of intellectual property (IP) related to Naglazyme (galsulfase) from SA Pathology, a unit of the Central Adelaide Local Health Network in Adelaide, Australia, in exchange for $81 million up front.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription